PublicWire | Emerging Market Stock News
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
  •  Home
  • Technology
  • Medical
  • Energy
  • Cannabis
  • Finance
  • Retail
  • General
  • Podcast
  • Videos
  • Services
No Result
View All Result
PublicWire
No Result
View All Result

Home » Cannabis » AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum

AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum

by PublicWire
April 27, 2019
in Cannabis
Reading Time: 3 mins read
0

NEW YORK, Jan. 18, 2017, AXIM, (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, entered a clinical trial on treating irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum at Wageningen University in the Netherlands.

The research team previously received approval from the Medical Ethical Committee (METC) of Wageningen University to study novel treatments for patients suffering from IBS. Functional, controlled-release Hemp oil CBD chewing gum and matching placebo gums will be tested for the clinical studies. The amount of the Hemp oil CBD gum is set at 50 mg CBD per serving. According to the trial protocol patients can use up to 6 chewing gums a day to control their stomach cramps, bloating, pain and other symptoms. The main study outcome is perceived pain reduction. Furthermore, the study will record general relief and change in stool frequency.

Designed by clinical investigators at Wageningen University and the AXIM Biotech team, the clinical trial will include a group of 40 patients age 18-65, diagnosed with IBS according to ROME III criteria to determine the effectiveness of CanChew Plus in alleviating IBS symptoms.

“We are pleased to have reached another milestone in the development of AXIM products to treat challenging health conditions,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “IBS is the most common functional gastrointestinal disorder affecting 9-15% of the worldwide population, and it has no sustainable cure.”

“The clinical trial at Wageningen University is the first of its kind to treat IBS symptoms by cannabinoid-containing chewing gum, and we look forward to sharing updates from the trial with you. With positive outcome from the IBS clinical trial, we are ready to proceed immediately with further trials on our pharmaceutical grade CanChew Rx™ products to treat inflammatory bowel disease (IBD), ulcerative colitis and Crohn’s disease. We are committed to finding research based cannabinoid solutions to help people suffering from gastrointestinal disorders and other health conditions with no effective remedies,” added George E. Anastassov, MD, DDS, MBA.

“IBS is a very common and often painful disorder which is still difficult to manage. People often experience sudden flare-ups and for many it has a negative impact on their quality of life. CBD has shown to have promising effects, but there has been a clear need for practical and effective formulations. Providing it via a chewing gum results in sustained release of the compound and better bio-availability,” said Renger Witkamp, Professor and Chair in Nutrition and Pharmacology of Wageningen University.

Wageningen University is a world-class education and research institute in the field of life sciences, agricultural and environmental science, and the only university in the Netherlands to focus on the theme of “healthy food and living environment.” According to the Times Higher Education World University Rankings, Wageningen is the best university in the Netherlands and No. 1 worldwide in agriculture and forestry for 2016 on the QS World University Rankings.

About AXIM®
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, visit www.AXIMBiotech.com.

About CanChew® and CanChew Plus®

CanChew® is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew® website include:

  • Non-habit forming
  • No prescription needed
  • Available in all 50 states
  • Great-tasting mint gum has no artificial sweeteners or preservatives
  • Non-GMO, gluten free, vegan and kosher

CanChew Plus® is a vastly improved delivery system than the alpha version of CanChew® Gum. It is produced by a leading European functional gum manufacturer.

Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLiving Foundation and honored with its Triple Leaf Award.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

 

 

 

 

Tags: AXIMAXIM BiotechnologiesCanchewcannabinoidCBDResearch
Previous Post

Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin®

Next Post

Mace to Acquire Washington Labs, Accelerating Growth in Personal Defense

PublicWire

At PublicWire, we know the vast majority of all investors conduct their due diligence and get their news online in a variety of ways including email, social media, financial websites, text messages, RSS feeds and audio/video podcasts. PublicWire’s financial communications program is uniquely positioned to reach these investors throughout the U.S. and Canada as well as on a global scale.

Related Posts

Photo by GRAS GRÜN on Unsplash
Cannabis

Zenabis returned $1.9 million worth of pot to Sundial over bad quality and visible molds

August 22, 2019
0
Photo by Rick Proctor on Unsplash
Cannabis

Tilray to start exporting medicinal pot to Germany

August 21, 2019
0
Photo by Esteban Lopez on Unsplash
Cannabis

CannTrust stocks fell another 5% after weed distributor returned millions worth of pot

August 20, 2019
0
Photo by Roberto Valdivia on Unsplash
Cannabis

Cannabis stocks fell as possible recession brews

August 14, 2019
0
Cannabis

Aurora Cannabis hovers trade flat amid strong market

August 13, 2019
0
Photo by Get Budding on Unsplash
Cannabis

Health inspectors flagged CannTrust’s non-compliance again, sending stocks down by 26%

August 12, 2019
0
Next Post

Mace to Acquire Washington Labs, Accelerating Growth in Personal Defense

Please login to join discussion

Subscribe To Our Newsletter

Loading
Ad
PublicWire | Emerging Market Stock News 24/7 | Investor Relations US Stock Market

© Copyright 2022 publicwire.com

Navigate Site

  • About
  • Contact Us
  • Disclaimer
  • Watch LIVE
  • Privacy Policy
  • Terms and Services
  • Contributors

Follow Us

No Result
View All Result
  • LIVE Investor News Channel
  • Cannabis
  • Energy
  • Finance
  • General
  • Medical
  • Podcasts
  • Retail
  • Technology
  • Videos

© Copyright 2022 publicwire.com

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.